Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Rheumatology
•
General Rheumatology
•
Infectious disease
Should we feel comfortable starting anti-TNF therapy in an otherwise low risk patient with borderline IGRA?
Should a CXR be pursued? Is there a difference in sensitivity/specificity of different IGRAs?
Related Questions
Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?
How do you approach biologic initiation in patients with inflammatory arthritis and repeatedly indeterminate Quantiferon?
Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?
How do you counsel immunosuppressed patients regarding a third Covid vaccination dose if they have had 2 doses of mRNA vaccine and either pre or post vaccine Covid infection?
Do you recommend re-vaccination in immunosuppressed patients who completed hepatitis B vaccine series but are found to have undetectable or low surface antibody titers?
How do you think about biologic use in patients with underlying HIV infection?
Which medications have the lowest risk of tuberculosis reactivation in patients with uncertain tuberculosis history and active rheumatologic disease?
When would you consider checking JC virus prior to initiating biologic therapy?
Are there any benefits of immediate vs delayed (1-2 weeks) cyclophosphamide while awaiting infectious work up in the setting of severe or organ threatening manifestations of autoimmune disease?
How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?